Menu
Search
|

Menu

Close
X

GW Pharmaceuticals PLC GWPH.OQ (NASDAQ Stock Exchange Global Market)

117.27 USD
-- (--)
As of Feb 22
chart
Previous Close 117.27
Open --
Volume --
3m Avg Volume 113,456
Today’s High --
Today’s Low --
52 Week High 143.37
52 Week Low 92.77
Shares Outstanding (mil) 2.11
Market Capitalization (mil) 2,975.41
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.12 Mean rating from 8 analysts

KEY STATS

Revenue (mm, GBP)
FY18
6
FY17
8
FY16
10
FY15
29
EPS (GBP)
FY18
-0.150
FY17
-0.434
FY16
-0.236
FY15
-0.178
*Note: Units in Millions of British Pounds
**Note: Units in British Pounds

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
178.97
8.08
Price to Book (MRQ)
vs sector
5.10
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
1.07
15.60
LT Debt to Equity (MRQ)
vs sector
1.03
12.18
Return on Investment (TTM)
vs sector
-37.10
13.67
Return on Equity (TTM)
vs sector
-38.68
15.40

EXECUTIVE LEADERSHIP

Geoffrey Guy
Executive Chairman of the Board, Since
Salary: $339,305.00
Bonus: --
Justin Gover
Chief Executive Officer, Director, Since 1999
Salary: $279,296.00
Bonus: --
James Noble
Non-Executive Deputy Chairman of the Board, Senior Independent Director, Since 2007
Salary: $61,984.00
Bonus: --
Adam George
Chief Financial Officer, Company Secretary, Director, Since 2012
Salary: $189,163.00
Bonus: --
Christopher Tovey
Chief Operating Officer, Executive Director, Since 2012
Salary: $205,370.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Sovereign House, Vision Park
CAMBRIDGE     00000

Phone: +441223.266800

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

SPONSORED STORIES